NEW
YORK, July 24, 2024 /PRNewswire/ -- The global
breast biopsy devices market size is estimated to grow by
USD 778.7 million from 2024-2028,
according to Technavio. The market is estimated to grow at a
CAGR of about 10.87% during the forecast period. Growing
prevalence of breast cancer cases is driving market
growth, with a trend towards paradigm shift towards
adoption of breast biopsy robot systems. However, high cost of
breast biopsy poses a challenge. Key market players include Advin
Health Care, Allengers Medical Systems Ltd., Argon Medical Devices
Inc., Becton Dickinson and Co.,
BIOPSYBELL Srl, Carestream Health Inc., Cook Group Inc., Danaher
Corp., FUJIFILM Corp., General Electric Co., Hologic Inc., IZI
Medical Products, Merit Medical Systems Inc.,
Metaltronica Spa, Planmed Oy, Scion Medical Technologies LLC,
Siemens Healthineers AG, Suretech Medical Inc., Vector Medical, and
Zamar Care.
Get a detailed analysis on regions, market
segments, customer landscape, and companies- View the
snapshot of this report
Breast Biopsy
Devices Market Scope
|
Report
Coverage
|
Details
|
Base year
|
2023
|
Historic
period
|
2018 - 2022
|
Forecast
period
|
2024-2028
|
Growth momentum &
CAGR
|
Accelerate at a CAGR of
10.87%
|
Market growth
2024-2028
|
USD 778.7
million
|
Market
structure
|
Fragmented
|
YoY growth 2022-2023
(%)
|
9.53
|
Regional
analysis
|
North America, Europe,
Asia, and Rest of World (ROW)
|
Performing market
contribution
|
North America at
36%
|
Key
countries
|
US, Germany, France,
China, and Canada
|
Key companies
profiled
|
Advin Health Care,
Allengers Medical Systems Ltd., Argon Medical Devices Inc., Becton
Dickinson and Co., BIOPSYBELL Srl, Carestream Health Inc., Cook
Group Inc., Danaher Corp., FUJIFILM Corp., General Electric Co.,
Hologic Inc., IZI Medical Products, Merit Medical Systems Inc.,
Metaltronica Spa, Planmed Oy, Scion Medical Technologies LLC,
Siemens Healthineers AG, Suretech Medical Inc., Vector Medical, and
Zamar Care
|
Market Driver
The breast biopsy devices market is experiencing significant
growth due to the increasing adoption of minimally invasive
procedures for breast cancer screening. Advanced technologies such
as robotic platforms, surgical navigation systems, and artificial
intelligence are in high demand to ensure accurate and efficient
surgical procedures. Hand-held needles and imaging-guidance systems
are commonly used for breast biopsies, but human errors during
these procedures can lead to inaccurate results. To address this
challenge, researchers have developed robotic systems like the
Sunram 5, an MRI-safe robot for breast biopsy, which helps in
localizing breast lesions and ensuring procedural efficacy.
Additionally, AI technology is being integrated into breast biopsy
systems to reduce human errors and improve healthcare outcomes.
This cutting-edge technology can provide doctors with accurate
data, enhance connectivity, and offer efficient screening to
patients. Vendors are focusing on developing advanced technological
solutions to improve traditional biopsy systems and provide
high-quality, effective breast biopsies.
The Breast Biopsy Devices market is witnessing significant
trends in needle biopsies and liquid biopsies for early cancer
detection. Liquid biopsies using circulating tumor cells and DNA
fragments offer a less invasive alternative to surgical breast
biopsies. The complexity of tumors calls for advancements in biopsy
techniques, leading to breakthroughs in therapy selection,
treatment monitoring, and recurrence monitoring. Skilled surgeons
and healthcare professionals utilize various devices such as biopsy
needles, guidance systems, biopsy tables, localization wires, and
assay kits for needle breast biopsies and surgical breast biopsies.
These devices are essential in surgical centers, hospitals,
research laboratories, pharmaceutical companies, and biotechnology
firms. The market is also influenced by clinical trials, cancer
conferences, webinar materials, breast cancer screening,
reimbursements, incidence of breast cancer, deaths caused by
invasive breast cancers, premalignant breast conditions, and
screening procedures. The market's growth is driven by the need for
accurate biopsy samples for diagnosis and treatment. However,
concerns regarding needle reuse and biopsy techniques continue to
impact market trends.
Discover 360° analysis of this market. For
complete information, schedule your consultation - Book
Here!
Market Challenges
- Breast biopsy procedures are essential for the early detection
and diagnosis of breast cancer. The increasing need for breast
cancer screening has led to a higher adoption rate of breast biopsy
devices globally. Mammograms, ultrasound, and MRIs are
commonly used to guide breast biopsies and locate abnormalities.
Needle biopsies are performed by physicians to investigate mass or
lump formations. Image-guided, minimally invasive breast biopsies
are conducted in hospitals, clinics, and cancer centers. Costs
vary, with insured patients paying an average of USD1,500-USD6,000
and uninsured patients USD2,500-USD6,500.
The high cost of image-guided procedures may hinder market growth.
Incorrect usage of guidance systems may lead to false results.
Reluctance to adopt novel technologies, particularly in developing
economies, and minimal acceptance among uninsured patients pose
challenges to the global breast biopsy devices market.
- The Breast Biopsy Devices market faces several challenges in
the diagnosis and treatment of breast cancer. Needle biopsies and
liquid biopsies are common methods, but the complexity of tumors
requires advanced techniques like circulating tumor cells and DNA
fragments detection. Clinical trials for breakthrough techniques
are ongoing. Skilled surgeons and healthcare professionals use
various devices such as biopsy needles, guidance systems, biopsy
tables, localization wires, and assay kits for surgical and liquid
breast biopsies. Early cancer detection is crucial for therapy
selection, treatment monitoring, and recurrence monitoring in
surgical centers, hospitals, research laboratories, pharmaceutical,
and biotechnology companies. Reimbursements, incidence of breast
cancer, deaths caused, invasive breast cancers, premalignant
breast, and screening procedures impact market growth. Needle reuse
and biopsy techniques are key concerns. Stay updated with
conference and webinar materials for the latest developments in
breast cancer and breast cancer screening.
For more insights on driver and
challenges - Request a sample report!
Segment Overview
This breast biopsy devices market report extensively covers
market segmentation by
- Product
- 1.1 Biopsy needles and systems
- 1.2 Biopsy image-guided systems
- 1.3 Others
- End-user
- 2.1 Hospitals
- 2.2 ASCs
- 2.3 Breast cancer specialty centers and clinics
- 2.4 Others
- Modality
- 3.1 Stereotactic x-ray guided breast biopsy
- 3.2 Ultrasound-guided breast biopsy
- 3.3 MRI-guided breast biopsy
- Geography
- 4.1 North America
- 4.2 Europe
- 4.3 Asia
- 4.4 Rest of World (ROW)
1.1 Biopsy needles and systems- The Breast Biopsy
Devices market is experiencing significant growth due to the
increasing prevalence of breast cancer and advancements in
diagnostic technology. Companies are innovating to develop more
accurate and less invasive devices, such as vacuum-assisted and
wireless biopsy systems. Market leaders include Becton, Dickinson
and Company, Hologic, and Siemens Healthineers. These companies are
expanding their product portfolios and investing in research and
development to stay competitive. The market is expected to continue
growing, driven by rising demand for early and accurate breast
cancer detection.
For more information on market segmentation with geographical
analysis including forecast (2024-2028) and historic data
(2017-2021) - Download a Sample Report
Learn and explore more about Technavio's in-depth research
reports
The global Breast Cancer Liquid Biopsy Testing Devices market is
experiencing robust growth due to increasing demand for
non-invasive diagnostic tools. As of 2024, the market is projected
to expand significantly, driven by advancements in biomarker
detection and rising awareness about early cancer detection. Key
players are innovating with enhanced technologies to improve
accuracy and accessibility. With growing prevalence of breast
cancer and heightened focus on personalized medicine, this market
is set to witness substantial growth, offering promising
opportunities for stakeholders and investors alike.
Research Analysis
The Breast Biopsy Devices market encompasses a range of tools
used in the diagnosis of breast cancer and pre-malignant
conditions. These devices include needle breast biopsy systems and
surgical breast biopsy instruments. The global market for breast
biopsy devices is driven by the increasing incidence of breast
cancer and deaths caused by it. According to the World Health
Organization, there were approximately 2.3 million cases of breast
cancer and 685,000 deaths in 2020. Early detection through breast
cancer screening procedures is crucial for effective therapy
selection and treatment monitoring. Liquid biopsy devices are
gaining popularity for their non-invasive approach in detecting
early-stage cancers and monitoring recurrence. The market for
breast biopsy devices spans across various end-users such as
surgical centers, hospitals, research laboratories, pharmaceutical
and biotechnology companies, and laboratory supplies.
Reimbursements and treatment accessibility are significant factors
influencing the market growth.
Market Research Overview
The Breast Biopsy Devices Market encompasses a range of tools
and technologies used in the diagnosis of breast cancer through
various biopsy procedures. These procedures include needle
biopsies, surgical breast biopsies, and liquid breast biopsies. The
global market for breast biopsy devices is driven by the high
incidence of breast cancer and deaths caused by invasive and
premalignant breast diseases. Reimbursements for breast cancer
screening and diagnostic procedures also play a significant role in
market growth. Breast cancer screening procedures aim to detect
early-stage cancers, allowing for effective treatment and improved
patient outcomes. Biopsy samples obtained through these procedures
are used for diagnosis, therapy selection, treatment monitoring,
and recurrence monitoring. The complexity of tumors and the need
for accurate and reliable diagnosis have led to the development of
breakthrough techniques such as liquid biopsy, which uses
circulating tumor cells and DNA fragments for diagnosis. Clinical
trials and research in the field of breast cancer continue to drive
innovation in breast biopsy devices. Skilled surgeons and
healthcare professionals use various biopsy needles, guidance
systems, biopsy tables, localization wires, and assay kits to
perform biopsies in surgical centers, hospitals, research
laboratories, and pharmaceutical and biotechnology companies. The
availability and accessibility of these devices are crucial for
effective cancer treatment and monitoring.
Table of Contents:
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation
- Product
-
- Biopsy Needles And Systems
- Biopsy Image-guided Systems
- Others
- End-user
-
- Hospitals
- ASCs
- Breast Cancer Specialty Centers And Clinics
- Others
- Modality
-
- Stereotactic X-ray Guided Breast Biopsy
- Ultrasound-guided Breast Biopsy
- MRI-guided Breast Biopsy
- Geography
-
- North America
- Europe
- Asia
- Rest Of World (ROW)
7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Trends
10 Company Landscape
11 Company Analysis
12 Appendix
About Technavio
Technavio is a leading global technology research and advisory
company. Their research and analysis focuses on emerging market
trends and provides actionable insights to help businesses identify
market opportunities and develop effective strategies to optimize
their market positions.
With over 500 specialized analysts, Technavio's report library
consists of more than 17,000 reports and counting, covering 800
technologies, spanning across 50 countries. Their client base
consists of enterprises of all sizes, including more than 100
Fortune 500 companies. This growing client base relies on
Technavio's comprehensive coverage, extensive research, and
actionable market insights to identify opportunities in existing
and potential markets and assess their competitive positions within
changing market scenarios.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
View original content to download
multimedia:https://www.prnewswire.com/news-releases/breast-biopsy-devices-market-size-is-set-to-grow-by-usd-778-7-million-from-2024-2028--growing-prevalence-of-breast-cancer-cases-boost-the-market-technavio-302204008.html
SOURCE Technavio